Ignite Creation Date:
2024-05-05 @ 4:55 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00347737
Status:
WITHDRAWN
Last Update Posted:
2013-01-16
First Post:
2006-06-30
Brief Title:
The Effects of Therapy With Teriparatide on Vascular Compliance and OsteoprotegerinRANKL
Sponsor:
Leland Graves III MD
Organization:
University of Kansas Medical Center
Study Overview
Official Title:
The Effects of Therapy With Teriparatide Recombinant Parathyroid Hormone 1-34 on Vascular Compliance and OsteoprotegerinRANKL
Status:
WITHDRAWN
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine what effect teriparatide will have on vascular blood vessel compliance and osteoprotegerin bone fluidand RANKL levels bone cells
Detailed Description:
Research subjects participation is about 6 months Subjects will give themselves daily injections of teriparatide after instruction on technique
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None